Mammal-specific domain of the prion protein may hold clues to neurodegenerative diseases

A study from Bochum describes a mammal-specific domain of the prion protein and offers new approaches for research into neurodegenerative diseases.

At first, they cause memory deficits and difficulties in walking, finally they inhibit elementary motor skills and destroy basic brain functions: Prion diseases are progressive and invariably fatal neurodegenerative diseases. They are caused by misfolded prion proteins. The mechanisms behind their development are still poorly understood. Researchers at Ruhr University Bochum, Germany, have now discovered a new region in prion proteins and thus identified a potential new area for research into neurodegenerative diseases. This domain is specific to mammalian prion proteins and influences the aggregation of the protein. The neuroscientists published their research results on April 22, 2024 in the Journal of Biological Chemistry.

Misfolded prion proteins disrupt the function of neurons in the brain

Prion diseases are very rare. About two in a million people are affected. One of the best-known examples is Creutzfeldt-Jakob disease, which gained particular prominence during the BSE crisis in the 1990s. As the disease progresses, the brain takes on a sponge-like perforated structure and shows protein deposits.

"The disease is triggered by the misfolding of the cellular prion protein, PrP for short, in the brain," explains Professor Jörg Tatzelt from the Institute of Biochemistry and Pathobiochemistry at Ruhr University Bochum, who led the study. "The pathological proteins accumulate in the brain and form aggregated deposits, so-called plaques. This gradually impairs the function of the neurons."

Prion diseases have so far only been confirmed in mammals. However, prion proteins are also found in the brains of frogs and reptiles. So why do they apparently not suffer from degenerative diseases?

The brains of frogs and reptiles developed much earlier in evolutionary history than the brains of mammals. Our assumption was that the biophysical and biochemical properties of the prion proteins have changed in the course of evolution and that the toxic misfolding only occurs in mammals."

Dr. Janine Kamps, first author 

Indications of a new function of the prion protein in mammals

To test their hypothesis, the researchers analyzed the folding of purified prion proteins from frogs and mice using fluorescence microscopy. After their studies, they compared the results. "We were able to identify a protein region that only occurs in the PrP of mice, in other words in the PrP of mammals, and that influences protein folding and -aggregation," explains Tatzelt, who is a Principal Investigator at the Research Department of Neuroscience at Ruhr University Bochum. "The structure of prions typically shows two subdomains in their formation - one structured and one intrinsically disordered," adds Kamps. Interestingly, the disordered region, the so-called N-terminal domain of the prion protein, has developed differently in mammals than in amphibians. This suggests a new function for mammalian PrP that the amphibian protein does not yet have.

The results contribute to a better understanding of the mechanisms of protein folding and could help to develop treatment approaches for prion diseases in the long term. The neuroscientists' next research project will build directly on the discoveries made. Tatzelt: "We will now investigate to what extent the mammalian-specific domain is associated with the ability of PrP to trigger neurodegenerative diseases."

Funding

The publication was funded by the German Research Foundation: Germany's Excellence Strategy - EXC 2033 - 390677874 - RESOLV and TA 167/6-3.

Source:
Journal reference:

Kamps, J., et al. (2024). Liquid-liquid phase separation of the prion protein is regulated by the octarepeat domain independently of histidines and copper. Journal of Biological Chemistry. doi.org/10.1016/j.jbc.2024.107310.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
A promising new strategy for malaria drug development